Sam-A Pharm. Co. Ltd (KQ:009300) — Stock Price
Sam-A Pharm. Co. Ltd (KQ:009300) is currently trading at ₩14030.00 KRW, up 0.00% today. Over the past 52 weeks, shares have ranged between ₩12130.00 and ₩17080.00. This page tracks Sam-A Pharm. Co. Ltd's live share price on the KQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see how much is Sam-A Pharm. Co. Ltd worth.
Sam-A Pharm. Co. Ltd (009300) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Sam-A Pharm. Co. Ltd's daily closing share price and trading volume on the KQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Sam-A Pharm. Co. Ltd Income Statement — Revenue, Profit & Earnings by Year
Sam-A Pharm. Co. Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | ₩77.80 Billion | ₩95.58 Billion | ₩97.21 Billion | ₩81.70 Billion | ₩54.67 Billion |
| Cost of Revenue | ₩31.44 Billion | ₩34.75 Billion | ₩35.59 Billion | ₩31.54 Billion | ₩22.01 Billion |
| Gross Profit | ₩46.36 Billion | ₩60.83 Billion | ₩61.62 Billion | ₩50.16 Billion | ₩32.66 Billion |
| Research & Development | ₩6.14 Billion | ₩5.42 Billion | ₩6.40 Billion | ₩3.77 Billion | ₩3.83 Billion |
| SG&A | ₩11.36 Billion | ₩28.66 Billion | ₩29.59 Billion | ₩26.66 Billion | ₩20.81 Billion |
| Total Operating Expenses | ₩66.82 Billion | ₩71.11 Billion | ₩73.71 Billion | ₩63.45 Billion | ₩48.62 Billion |
| Operating Income | ₩10.98 Billion | ₩24.47 Billion | ₩23.50 Billion | ₩18.25 Billion | ₩6.05 Billion |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | ₩6.05 Billion |
| Interest Expense | ₩441.06 Million | ₩538.22 Million | ₩219.74 Million | ₩63.43 Million | ₩125.61 Million |
| Income Before Tax | ₩16.03 Billion | ₩29.27 Billion | ₩28.48 Billion | ₩18.40 Billion | ₩5.33 Billion |
| Income Tax Expense | — | — | — | — | ₩1.94 Billion |
| Net Income | ₩12.94 Billion | ₩22.08 Billion | ₩21.37 Billion | ₩11.91 Billion | ₩3.39 Billion |
Sam-A Pharm. Co. Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Sam-A Pharm. Co. Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | ₩247.04 Billion | ₩248.73 Billion | ₩231.31 Billion | ₩203.20 Billion | ₩189.17 Billion |
| Total Current Assets | ₩135.87 Billion | ₩113.09 Billion | ₩117.99 Billion | ₩116.86 Billion | ₩82.36 Billion |
| Cash & Equivalents | — | ₩9.55 Billion | ₩9.02 Billion | ₩9.17 Billion | ₩7.98 Billion |
| Short-term Investments | ₩91.06 Billion | ₩59.45 Billion | ₩70.09 Billion | ₩68.20 Billion | ₩45.00 Billion |
| Net Receivables | ₩19.47 Billion | ₩20.50 Billion | ₩22.60 Billion | ₩21.47 Billion | ₩18.04 Billion |
| Inventory | ₩16.47 Billion | ₩14.28 Billion | ₩13.01 Billion | ₩12.24 Billion | ₩9.34 Billion |
| Property, Plant & Equipment | — | ₩42.75 Billion | ₩40.51 Billion | ₩37.16 Billion | ₩40.19 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | ₩18.93 Billion | ₩28.76 Billion | ₩30.84 Billion | ₩22.58 Billion | ₩17.15 Billion |
| Total Current Liabilities | ₩13.89 Billion | ₩20.51 Billion | ₩21.14 Billion | ₩21.56 Billion | ₩14.59 Billion |
| Long-term Debt | — | ₩2.28 Billion | ₩2.50 Billion | ₩0.00 | ₩0.00 |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | ₩228.11 Billion | ₩219.98 Billion | ₩200.47 Billion | ₩180.62 Billion | ₩172.02 Billion |
| Retained Earnings | ₩204.17 Billion | ₩196.48 Billion | ₩179.20 Billion | ₩160.35 Billion | ₩149.84 Billion |
Sam-A Pharm. Co. Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Sam-A Pharm. Co. Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩10.72 Billion | ₩25.25 Billion | ₩20.76 Billion | ₩19.60 Billion | ₩12.94 Billion |
| Capital Expenditures | ₩1.78 Billion | ₩6.51 Billion | ₩3.82 Billion | ₩239.25 Million | ₩275.44 Million |
| Free Cash Flow | ₩8.94 Billion | ₩18.74 Billion | ₩16.94 Billion | ₩19.37 Billion | ₩12.67 Billion |
| Investing Cash Flow | — | ₩-21.41 Billion | ₩-20.81 Billion | ₩-13.03 Billion | ₩-19.80 Billion |
| Financing Cash Flow | — | ₩-3.52 Billion | ₩-111.77 Million | ₩-5.38 Billion | ₩-3.67 Billion |
| Dividends Paid | ₩-4.88 Billion | ₩4.58 Billion | ₩2.44 Billion | ₩1.53 Billion | ₩1.83 Billion |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | ₩4.81 Billion | ₩4.25 Billion | ₩3.88 Billion | ₩3.17 Billion | ₩3.70 Billion |
| Change in Cash | ₩-2.97 Billion | ₩531.73 Million | ₩-156.46 Million | ₩1.19 Billion | ₩-10.41 Billion |
Sam-A Pharm. Co. Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Sam-A Pharm. Co. Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Dec 31, 2025 | 658.38 | — | — |
| Sep 30, 2025 | -8.86 | — | — |
| Jun 30, 2025 | 441.17 | — | — |
| Mar 31, 2025 | 1029.43 | — | — |
| Dec 31, 2024 | 698.82 | — | — |
| Sep 30, 2024 | 344.63 | — | — |
| Jun 30, 2024 | 1040.13 | — | — |
| Mar 31, 2024 | 1534.05 | — | — |